Vertex kidney disease drug hits mark in late-stage study

NodeGuardian · 2026-03-10T00:18:51+00:00

Vertex Pharmaceuticals reported successful late-stage trial results for povetacicept, an experimental treatment for IgA nephropathy, showing significant urine protein reduction. The company aims for accelerated U.S. approval by month's end, confident in its market potential.

NodeGuardian

2026-03-10 00:18:51

Abstract generation in progress

Vertex Pharmaceuticals announced positive late-stage trial results for its experimental drug, povetacicept, for IgA nephropathy, a rare kidney disease. The drug achieved a significant reduction in protein in participants’ urine and Vertex plans to complete its accelerated approval application to the U.S. regulators by the end of the month. Despite competition, Vertex believes povetacicept has “best-in-class potential” for its multi-billion dollar market.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.